Creon IR + Creon® (DR/GR)
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Exocrine Pancreatic Insufficiency in Subjects With Cystic Fibrosis
Conditions
Exocrine Pancreatic Insufficiency in Subjects With Cystic Fibrosis
Trial Timeline
Mar 1, 2015 → Jul 1, 2015
NCT ID
NCT02415959About Creon IR + Creon® (DR/GR)
Creon IR + Creon® (DR/GR) is a phase 2 stage product being developed by AbbVie for Exocrine Pancreatic Insufficiency in Subjects With Cystic Fibrosis. The current trial status is completed. This product is registered under clinical trial identifier NCT02415959. Target conditions include Exocrine Pancreatic Insufficiency in Subjects With Cystic Fibrosis.
What happened to similar drugs?
3 of 4 similar drugs in Exocrine Pancreatic Insufficiency in Subjects With Cystic Fibrosis were approved
Approved (3) Terminated (2) Active (1)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02415959 | Phase 2 | Completed |
Competing Products
6 competing products in Exocrine Pancreatic Insufficiency in Subjects With Cystic Fibrosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Pancrelipase in combination with Ensure Plus | Johnson & Johnson | Phase 1 | 29 |
| Pancrease MT 10.5, or MT 21 + Placebo for Pancrease MT 10.5 or MT 21 | Johnson & Johnson | Phase 3 | 40 |
| CREON | AbbVie | Approved | 35 |
| Pancrelipase + Placebo | AbbVie | Approved | 35 |
| Pancrelipase Capsules | AbbVie | Approved | 50 |
| Lipacreon | Viatris | Pre-clinical | 23 |